I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
Articles
The many welcome comments to the Alzheimer’s piece that posted a couple of weeks ago prompt me to supply answers (if I am able to do that), but also set my mind to wandering on the fringes of a number of issues that may be of interest to the Gumshoe constituency. Anavex 2-73 At the […]
From where I sit, it seems to me that the entire landscape of Alzheimer’s disease (AD) has changed, and changed quite significantly. The litany of announcements from pharmaceutical companies big and small revealing the unfortunate news that yet another promising agent for the treatment of AD has failed to meet its objectives in a […]
Here’s the lead-in to the ad that caught our readers’ attention this week: “This ‘Perfect Storm’ Stock Is Set to Deliver Big Pharma a Swift and Devastating DEATHBLOW It Won’t Come Back From… “And Launch This Little Company on A 72-Hour, $8.98 Billion All-Out SPRINT” And there’s a deadline… today, in fact, when there will […]
This is an odd one, so be forewarned. A bunch of readers jumped in to ask me about emails coming out of Investorplace that pitch a tiny private company heading into FDA approval as the focus of their “Blockbuster FDA Approval Summit 2019” presentation… and yes, of course, the Mighty, Mighty Thinkolator can tell you […]
Is this going to be good news, or bad news, or somewhere in between? On balance, I would say good news, simply because the research and investigation is going on at an intense pace. Currently there are 1,903 clinical trials underway at some stage, in the US and all over the world. When I first […]
Dave Lashmet has teased a handful of biotech stocks since starting the Stansberry Venture service a couple years ago, and they usually get a lot of attention from our readers — so the new ad from Lashmet today has been forwarded to me dozens of times already. And while I’m not sure we’ll be able […]
[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Eisai is a partner with Biogen on aducanumab. ESALY is < $90 per share as opposed to BIIB at $285. ....
Another failure in Alzheimer's Disease trials... BIIB and Eisai discontinued their late Phase 3 trials because they were...
I think it must be Eisai Co Ltd OTC Pink - ESALY. Denali doesn't LL it would have the ability to market Tumor Paint wo...
well we already own Eisai, ESALY so we can wait this pitch out....
After Lashmet's last pitch, I bought Eisai (ESALY) thinking that it was sure to double. I have received a couple of div...